

Efficient anticoagulant testing worldwide



SACT-II

A simple, inexpensive screening method for the detection of circulating lupus anticoagulants



SACT-II

A simple, inexpensive screening method for the detection of circulating Lupus anticoagulants (LA)

- Clearer reagent, clotting can be tested in any photoelectric clotting devices
- KCT and SACT II results on various LA plasmas is extremely good with a correlation of 0.99.
- Stability: 2 years at 2-8°C

Surface Activated Clotting Time-II (**SACT-II**) reagent is a clear, stable, phospholipid-free suspension of an aluminosilicate mineral which activates contact factors similarly to kaolin or silica. The SACT-II reagent can thus be used as a substitute for kaolin suspension in kaolin clotting time (KCT) or silica clotting time tests as a screening test for LA, running in regular APTT mode on automated clotting instruments. Abnormal results need to be followed up mixing tests with normal plasma, use of HRRS (if heparin is suspected) and factor assays.

GRAPH: SACT-II vs KCT Correlation




Figure shows the correlation between SACT-II and KCT results on LA (▲) and other plasmas (●)

PRODUCT	REF	SIZE	STATUS
SACT-II	X9601	5x10 ml	RUO

REFERENCES:

1. Exner T, Rickard KA, Kronenberg H. A sensitive test demonstrating lupus anticoagulant and its behavioural patterns. *Brit J Haematol*.1978;40;143-151.
2. Chantarangkul V, Tripodi A, Arbini KMA, Mannucci PM. Silica clotting time as a screening and confirmatory test for lupus anticoagulants. *Thromb. Res.* 1992; 67; 355-365.
3. Lesperance B, et al. Relative sensitivity of different tests in the detection of low titer lupus anticoagulants. *Thromb Haemost.* 1988; 60;217-9.
4. Galli M, Finazzi G, Bevers EM. Kaolin clotting time and dilute Russells viper venom time distinguish between prothrombin dependent and beta 2 glyco-protein I dependent antiphospholipid antibodies. *Blood* 1995; 86; 617-623.
5. Brandt JT, et al. Criteria for the diagnosis of lupus anticoagulants: An update. *Thromb. Haemostas.* 1995; 74;1185-1190.
6. Exner T, et. al. Effect of an activated charcoal product (DOAC STOPTM) intended for extracting DOAC on various other APTT-prolonging agents. *Clin Chem Lab Med.* 2019; 57; 690-696
7. Eby C. Antiphospholipid syndrome review. *Clin. Lab Med.* 2009; 29; 305-319.
8. Devreese K, Hoylaerts MF. Laboratory diagnosis of the antiphospholipid syndrome: a plethora of obstacles to overcome. *Eur J Haematol.* 2009 Jul;83(1):1-16.



Dr Thomas Exner founded Haematex in 2004, his motivation was to increase coagulation lab efficiency by improving and innovating diagnostic reagents. Haematex products are designed, manufactured and distributed under the highest standard of quality and safety.

“Thrombosis and haemorrhage affect many clinical decisions, their control can impact treatment outcomes and indeed - life itself.”

- Dr Thomas Exner



Suite 9/17 King Rd,
Hornsby 2077 NSW
Australia



www.haematex.com

Email: info@haematex.com
Phone: (+61) 2 9482 2288